[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ras-family-oncogene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"RAS Family Oncogene",23,20,[8,16,23,29,35,41,47,53,59,66,72,78,84,90,96,102,108,114,120,126,132,139,146],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05828069","A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis",[12],"Phase 2","RECRUITING","2026-08-26T02:16:16.995720Z","2026-05-05T02:43:29.729634Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06299839","PAS-004 in Patients With Advanced Solid Tumors",[20],"Phase 1","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.322222Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07446322","FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer",[12],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.132436Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06634875","Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)",[12],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.530208Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06654037","Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer",[20],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.017987Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06959550","Phase II Study of Anti-PD-1\u002FVEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer",[12],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:27.636070Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06884618","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.591431Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.103317Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",[63],"Phase 1\u002FPhase 2","2026-08-26T02:18:51.833592Z","2026-05-05T02:43:26.935632Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06194929","Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",[63],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.716817Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07405476","Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment",[12],"2026-08-26T02:15:11.740957Z","2026-05-05T02:35:31.608468Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06983743","A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:18:21.216897Z","2026-07-05T03:45:20.456891Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05379985","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",[63],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.015195Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06804824","A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.192980Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07397338","Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",[63],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.800389Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:29.586102Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06904066","Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",[20],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:27.428326Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[20],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT07638371","A Study of MSK-TCR5 in People With Solid Tumor Cancers",[20],"2026-08-26T02:18:29.369233Z","2026-06-14T18:39:22.257001Z",{"nct_id":133,"title":134,"phases":135,"status":136,"updated_at":137,"content_modified":138},"NCT07053020","A Phase 1b\u002F2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)",[63],"NOT_YET_RECRUITING","2026-08-26T02:18:47.742071Z","2026-04-29T02:57:57.064123Z",{"nct_id":140,"title":141,"phases":142,"status":143,"updated_at":144,"content_modified":145},"NCT06232655","Cladribine Venetoclax in Monocytic AML",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:26:30.254593Z","2026-05-05T02:43:29.588320Z",{"nct_id":147,"title":148,"phases":149,"status":143,"updated_at":150,"content_modified":151},"NCT06507306","A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[20],"2026-08-03T02:23:21.062956Z","2026-04-29T02:57:57.103001Z"]